Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Motesanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 18/20 | 0.95 |
| ▸ | RET known ✓ | P07949 | 2/20 | 0.95 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.95 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.95 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.95 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.95 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.95 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.95 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.95 |
| ▸ | CIT | O14578 | 1/20 | 0.95 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.95 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.95 |
| ▸ | STK10 | O94804 | 1/20 | 0.95 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.95 |
| ▸ | ABL1 | P00519 | 1/20 | 0.95 |
| ▸ | EGFR | P00533 | 1/20 | 0.95 |
| ▸ | RAF1 | P04049 | 1/20 | 0.95 |
| ▸ | LCK | P06239 | 1/20 | 0.95 |
| ▸ | FYN | P06241 | 1/20 | 0.95 |
| ▸ | CSF1R | P07333 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Motesanib SCHEMBL446673 | 1.00 | KDR (0.95) | KDRRETMAP3K20RIPK3CIT | |
| Motesanib SCHEMBL29361754 | 1.00 | KDR (0.95) | KDRRETMAP3K20RIPK3CIT | |
| Motesanib SCHEMBL187470 | 0.97 | KDR (1.00) | KDRRETMAP3K20RIPK3CIT | |
| Motesanib SCHEMBL29354461 | 0.97 | KDR (1.00) | KDRRETMAP3K20RIPK3CIT | |
| Motesanib SCHEMBL445079 | 0.96 | KDR (0.98) | KDRRETMAP3K20RIPK3CIT | |
| SCHEMBL3150119 | 0.89 | KDR (0.85) | KDRRETMAP3K20RIPK3CIT | |
| SCHEMBL4537062 | 0.87 | KDR (0.81) | KDRRETMAP3K20RIPK3CIT | |
| SCHEMBL3144781 | 0.87 | KDR (0.81) | KDRRETMAP3K20RIPK3CIT | |
| SCHEMBL3155345 | 0.86 | KDR (0.79) | KDRRETMAP3K20RIPK3CIT | |
| SCHEMBL444347 | 0.86 | KDR (0.79) | KDRRETMAP3K20RIPK3CIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4640714-A2 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML Screening, LLC (US) | 2025-10-29 | — | — | EP | claimed |
| US-12350261-B2 | Methods and devices for the treatment of ocular diseases in human subjects | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-07-08 | — | — | US | claimed |
| EP-4490695-A1 | ARTIFICIAL INTELLIGENCE ARCHITECTURE FOR PREDICTING CANCER BIOMARKERS | The Regents of the University of California (US) | 2025-01-15 | — | — | EP | claimed |
| US-20240293419-A1 | COMBINATION THERAPY FOR TREATING CANCER | EPIZYME INC (US) | 2024-09-05 | — | — | US | claimed |
| EP-4378957-A2 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | Novartis AG (CH) | 2024-06-05 | — | — | EP | claimed |
| EP-4177356-B1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML SCREENING LLC (US) | 2024-05-08 | — | — | EP | claimed |
| WO-2023172929-A1 | ARTIFICIAL INTELLIGENCE ARCHITECTURE FOR PREDICTING CANCER BIOMARKERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-09-14 | — | — | WO | claimed |
| EP-4177356-A1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML Screening, LLC (US) | 2023-05-10 | — | — | EP | claimed |
| EP-3625368-B1 | METHODS FOR ASSESSING THE RISK OF DEVELOPING PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY CAUSED BY JOHN CUNNINGHAM VIRUS BY GENETIC TESTING | PML SCREENING LLC (US) | 2022-11-09 | — | — | EP | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260144935-A1 | DRIVE ASSEMBLY FOR A DRUG DELIVERY DEVICE AND RELATED METHODS | AMGEN INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4107166-B1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747275-A1 | VECTORS INCORPORATING A COMBINATION OF PROMOTERS DRIVING SELECTABLE MARKER EXPRESSION | Amgen Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122094689-A | Combination therapy of diacylglycerol kinase (DGK) alpha inhibitors with other therapies | — | 2026-05-26 | — | — | CN | disclosed |
| CN-113990437-A | System and method for remotely processing data collected by a drug delivery device | 安姆根有限公司 | 2022-01-28 | — | — | CN | disclosed |
| US-20220025036-A1 | USE OF IL-1BETA BINDING ANTIBODIES | NOVARTIS AG (CH) | 2022-01-27 | — | — | US | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3943135-A2 | DRUG INJECTION DEVICE WITH VISUAL AND AUDIBLE INDICATORS | Amgen Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3941928-A1 | ALTERNATE DETERGENTS FOR VIRAL INACTIVATION | Amgen Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-11230589-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230589-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | KDR 1552/4885RET 1865/4885PDGFRB 234/4885 |
| US-20240293419-A1 | COMBINATION THERAPY FOR TREATING CANCER | EZH2, BMI1, DOT1L | KDR 17/4885RET 81/4885PDGFRB 201/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | KDR 63/4885RET 657/4885PDGFRB 632/4885 |
| US-20220025036-A1 | USE OF IL-1BETA BINDING ANTIBODIES | IL1B, IL1RN, IL1A | KDR 503/4885RET 1500/4885PDGFRB 42/4885 |
| US-20260144935-A1 | DRIVE ASSEMBLY FOR A DRUG DELIVERY DEVICE AND RELATED METHODS | CRH, PDE1C, DYNLL2 | KDR 387/4885RET 3180/4885PDGFRB 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.